Versant Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Versant Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-84	Closed	–	–	1740
2019 Q3	$0	Hold	84	–	–	﹤0.01%	1746
2019 Q2	$0	Buy	+84	New	+$272	﹤0.01%	1890
2016 Q4	–	Sell	-399	Closed	-$1K	–	1628
2016 Q3	$1K	Hold	399	–	–	﹤0.01%	1351
2016 Q2	$1K	Sell	399 -217	-35%	-$724	﹤0.01%	1320
2016 Q1	$2K	Sell	616 -1,007	-62%	-$3.14K	﹤0.01%	1192
2015 Q4	$5K	Buy	+1,623	New	+$6.79K	﹤0.01%	967

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Versant Capital Management's PDLI Position: Q4 2019 in Review

Versant Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2019, closing a stake of 84 shares.

Versant Capital Management first reported a position in PDLI in Q4 2015 and held it in 6 quarters. The position peaked at $5K in Q4 2015. 150 funds tracked by Wall St. Rank hold PDLI as of Q4 2019.

Versant Capital Management reported no remaining PDL BioPharma, Inc. position as of Q4 2019 after selling out during the quarter.
Versant Capital Management sold 84 PDL BioPharma, Inc. shares in Q4 2019.
Versant Capital Management first reported a position in PDL BioPharma, Inc. in Q4 2015 and held it in 6 quarters.
Versant Capital Management's PDL BioPharma, Inc. position peaked at $5K in Q4 2015.
150 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2019.

Based on Versant Capital Management's 13F filing for Q4 2019, filed 28 Jan 2020.